CLM-SAP 17: Guidelines in Clinical Lipidology: Concepts and Controversies

Title:

CLM-SAP 17: Guidelines in Clinical Lipidology: Concepts and Controversies

Topic: Cardiology
Relevant Terms: Guidelines/Recommendations
Primary Audience: Cardiologists, Cardiovascular Nurses, Endocrinologists, Family Practitioners, Internists, Lipidologists, Lipid Specialists, Nephrologists, Nurse Practitioners, Pharmacists, Dietitians, PhDs, Physicians Assistants, Primary Care Physicians
Launch Date: 03-Feb-15
Credits: AMA PRA Category 1 Credits
4 ACPE contact hours
4 ANCC contact hours
4 CDR continuing professional education units
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Compare and contrast approaches to lipid management for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol
  2. Analyze the effectiveness of risk assessment approaches of the NLA's Recommendations for Patient-Centered Management of Dyslipidemia and the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol
  3. Recognize differences in lipid management recommendations for special populations
  4. Compare and contrast the role of lifestyle and pharmacologic therapies for ASCVD prevention advocated by the NLA's Recommendations for Patient-Centered Management of Dyslipidemia with the 2013 ACC/AHA Guideline for the Treatment of Blood Cholesterol
    PROGRAM OVERVIEW
    Cardiovascular disease remains the leading cause of morbidity and mortality in the United States. In order to improve the quality of preventive therapies, clinical practice guidelines and recommendations related to lipid management to reduce atherosclerotic cardiovascular risk are routinely updated and released. As different approaches are advocated, clinicians should become familiar with all available guidelines and recommendations in order to implement an informed, evidence-based approach to patient care. This program will review similarities and differences among these important guidelines in order to reduce gaps in implementation of evidence-based therapies.  
     
    RELEASE DATE: February 3, 2015
    EXPIRATION DATE: February 2, 2018
     
    ACTIVITY FORMAT: Internet activity enduring material
     
    CRITERIA FOR SUCESS
    In order to receive credit for this enduring program, participants must answer each question, review the ensuing critiques and evaluate the activity. To receive credit you must obtain a 70% or greater total score on your Performance Score Report. A statement of credit will be available upon completion of an evaluation form. If you have questions about this CME/ CE activity, please contact the NLA at cme@lipid.org.
     
    For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
     
    ACTIVE LEARNING
    NLA and AKH have structured this exercise to actively engage the participant in discovery of their knowledge, and in their ability to apply into practice through clinical vignettes/case scenarios. Once the self-assessment questions are graded, the participant has the opportunity to review their answers and critiques for each question and seek out additional information through references provided.
     
    Physicians who complete a program evaluation will receive a Statement of Continuing Education Credit from the NLA for up to 4 hours of AMA PRA Category 1 Credits™ toward the AMA Physician Recognition Award. 
     
     
    CREDIT DESIGNATION
    CME credit provided by the National Lipid Association
     
    Physicians
    The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    The National Lipid Association designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
     
    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
     
    Dietitians
    The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 4 Continuing Education Units (CPEUs) for completion of this activity. CDR Accredited Provider #NL0002.
     
    CE credit provided by AKH Inc., Advancing Knowledge in Healthcare
     
    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 4 contact hours (0.4 CEUs). UAN 0077-9999-15-007-H04-P. Initial Release Date: February 3, 2015.
     
    Nursing
    AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
    This activity is awarded 4 contact hours. 
     
    Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and the National Lipid Association.
     
    COMMERCIAL SUPPORT
    There is no commercial support for this activity. 
     
    PROGRAM FACULTY
     
    Carl E. Orringer, MD, FACC, FNLA*
    EDITOR-IN-CHIEF
    Associate Professor of Medicine
    University of Miami Miller School of Medicine
    Miami, FL
     
    Pamela B. Morris, MD, FACC, FACP, FACPM, FAHA, FNLA*
    Director, Seinsheimer Cardiovascular Health Program
    Co-Director, Women's Heart Care
    Medical University of South Carolina
    Charleston, SC  
     
    Peter H. Jones, MD, FNLA*
    Associate Professor
    Department of Medicine, Center for Cardiovascular
    Disease Prevention
    Baylor College of Medicine
    Houston, TX
     
    *Denotes Diplomate, American Board of Clinical Lipidology.
     
    FACULTY DISCLOSURES
    NAME
    RELATIONSHIP
    COMPANY
    Peter Jones, MD
    Consultant
    Amgen, Atherotech, Inc., Merck & Co., Inc., Sanofi-aventis/Regeneron Pharmaceuticals, Inc.
    Speakers Bureau
    Merck & Co., Inc.
    Pamela Morris, MD
    Advisory Board
    Aegerion Pharmaceuticals, Inc., AstraZeneca, Genzyme Corporation
    Speakers Bureau
    Aegerion Pharmaceuticals, Inc., AstraZeneca, Genzyme Corporation
    Carl Orringer, MD
    Consultant
    Merck & Co., Inc.
    PLANNER DISCLOSURES
    Robert Wild, MD, PhD, MPH (CME Reviewer)
    Consultant
    Atherotech, Inc.
    AKH Staff/Planners
    N/A
    Nothing to Disclose
    NLA Staff/Planners
    N/A
    Nothing to Disclose
     
    Disclosure Declaration
    It is the policy of the NLA and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent  and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. NLA/AKH planners and reviewers have no relevant financial relationships to disclose.
     
    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. NLA, AKH Inc., the author(s) and the publisher specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of the content.
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above